Lisata TherapeuticsLSTA
About: Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.
Employees: 26
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
5% more funds holding
Funds holding: 20 [Q3] → 21 (+1) [Q4]
2% more capital invested
Capital invested by funds: $2.3M [Q3] → $2.33M (+$38.7K) [Q4]
0.14% more ownership
Funds ownership: 9.21% [Q3] → 9.35% (+0.14%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Research analyst outlook
We haven’t received any recent analyst ratings for LSTA.
Financial journalist opinion
Based on 8 articles about LSTA published over the past 30 days









